Comparison of combination chemotherapy programs in advanced adenocarcinoma-large cell carcinoma of the lung: A north central cancer treatment group study

J. E. Krook, T. R. Fleming, R. T. Eagan, S. Cullinan, D. Pfeifle, T. Elliott, P. Etzell

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

One hundred and six patients with advanced adrenocarcinoma and large cell carcinoma of the lung with no prior chemotherapy were entered in a prospectively randomized trial comparing cyclophosphamide, doxorubicin, and cisplatin versus methotrexate, doxorubicin, cyclophosphamide, and lomustine. The two regimens resulted in nearly identical regression probabilities (36% vs 34%), distributions of time to progression, and survival distributions. The major toxic effects from both regimens consisted primarily of myelosuppression and nausea and vomiting, with severe vomiting occurring more frequently in patients treated with cyclophosphamide, doxorubicin, and cisplatin (43% vs 19%).

Original languageEnglish (US)
Pages (from-to)493-498
Number of pages6
JournalCancer Treatment Reports
Volume68
Issue number3
StatePublished - Jun 15 1984

Fingerprint Dive into the research topics of 'Comparison of combination chemotherapy programs in advanced adenocarcinoma-large cell carcinoma of the lung: A north central cancer treatment group study'. Together they form a unique fingerprint.

Cite this